Skip to main content

Table 2 Correlation of clinic-pathological features with MALAT1 expression in PCa TMA corhort

From: MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer

  Cases Negative Low Positive High Positive pValue (X2)
(Tot 71)
Normal 8–11.3% 7–87.5% 1–12.5% 0–0% 0.001
Cancer 63–88.7% 12–19% 37–58.7% 14–22.2%
T1-T2 30–47.6% 6–20% 23–76.7% 1–3.3% 0.006
T3-T4 33–52.4% 6–18.2% 14–42.4% 13–39.4%
N0 51–80.9% 11–21.6% 34–66.7% 6–11.7% 0.001
N1 12–19.1% 1–8.3% 3–25% 8–66.7%
M0 55–87.3 11–20% 35–63.7% 9–16.3% 0.001
M1 8–12.7% 1–12.5% 2–25% 5–62.5%
Stage 1-2 30–47.6% 6–20% 23–76.7% 1–3.3% 0.001
Stage 3-4 33–52.4% 6–18.2% 14–42.4% 13–39.4%
WHO Grade 1-2 24–38.1% 6–25% 17–70.8% 1–4.2% 0.001
WHO Grade 3-4 37–58.7% 5–13.5% 19–51.4% 13–35.1%
  1. Spearman’s Rho bivariate analysis correlationcoefficient indicates a positive correlation between Malat1 histopathological score and patient’s clinical parameters analyzed. Correlations are significant at the 0.01 and 0.05 levels (2-tailed). The X squared tests of contingency performed between the same factors is significant with a p-value < 0.01. Frequency tables and all the statistical analyses were performed using IBM SPSS Ver. 25